Welcome to our dedicated page for Revolution SEC filings (Ticker: RVMDW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Revolution's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Revolution's regulatory disclosures and financial reporting.
Revolution Medicines is offering $750,000,000 of common stock, equal to 7,777,662 shares at an assumed public offering price of $96.43 per share. The prospectus supplement also describes a concurrent offering of $250,000,000 aggregate principal amount of convertible senior notes due 2033 (plus a $37,500,000 option).
The company reported 197,001,401 shares outstanding as of December 31, 2025. The shelf registration permits primary sales of common stock; the underwriters have a 30-day option to purchase up to $112,500,000 of additional shares. Completion of the equity offering is not contingent on the concurrent convertible note offering, and vice versa.
Revolution Medicines is offering $750,000,000 of common stock, equal to 7,777,662 shares at an assumed public offering price of $96.43 per share. The prospectus supplement also describes a concurrent offering of $250,000,000 aggregate principal amount of convertible senior notes due 2033 (plus a $37,500,000 option).
The company reported 197,001,401 shares outstanding as of December 31, 2025. The shelf registration permits primary sales of common stock; the underwriters have a 30-day option to purchase up to $112,500,000 of additional shares. Completion of the equity offering is not contingent on the concurrent convertible note offering, and vice versa.
Revolution Medicines, Inc. is offering $250,000,000 aggregate principal amount of % convertible senior notes due 2033, with an underwriter option of up to $37,500,000. The notes pay semi‑annual interest, mature May 1, 2033 and are convertible into common stock based on an initial conversion rate and conversion price.
The offering is concurrent with a separate common stock offering of $750,000,000 (plus up to $112,500,000 option). No listing is planned for the notes; common stock trades on Nasdaq under RVMD and last reported sale price was $96.43 per share.
Revolution Medicines, Inc. is offering $250,000,000 aggregate principal amount of % convertible senior notes due 2033, with an underwriter option of up to $37,500,000. The notes pay semi‑annual interest, mature May 1, 2033 and are convertible into common stock based on an initial conversion rate and conversion price.
The offering is concurrent with a separate common stock offering of $750,000,000 (plus up to $112,500,000 option). No listing is planned for the notes; common stock trades on Nasdaq under RVMD and last reported sale price was $96.43 per share.
Revolution Medicines reported strong topline results from its global Phase 3 RASolute 302 trial of oral daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. Daraxonrasib improved median overall survival to 13.2 months versus 6.7 months with standard intravenous chemotherapy, with a hazard ratio of 0.40 (p < 0.0001). The therapy also showed statistically significant, clinically meaningful gains in progression-free survival and was generally well tolerated, with a manageable safety profile and no new safety signals. Based on this first interim analysis, all progression-free and overall survival endpoints are considered final, and the company plans to submit these data to global regulators, including a future U.S. New Drug Application under a Commissioner’s National Priority Voucher.
Revolution Medicines reported strong topline results from its global Phase 3 RASolute 302 trial of oral daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. Daraxonrasib improved median overall survival to 13.2 months versus 6.7 months with standard intravenous chemotherapy, with a hazard ratio of 0.40 (p < 0.0001). The therapy also showed statistically significant, clinically meaningful gains in progression-free survival and was generally well tolerated, with a manageable safety profile and no new safety signals. Based on this first interim analysis, all progression-free and overall survival endpoints are considered final, and the company plans to submit these data to global regulators, including a future U.S. New Drug Application under a Commissioner’s National Priority Voucher.
The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting 0 shares (0%) of Revolution Medicines Inc common stock (CUSIP 76155X100). The filing states an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that disaggregated certain subsidiaries' holdings from The Vanguard Group, Inc. The Schedule lists the filing address as 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
The filing declares no sole or shared voting or dispositive power over any Revolution Medicines shares and confirms ownership of 5% or less of the class.
The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting 0 shares (0%) of Revolution Medicines Inc common stock (CUSIP 76155X100). The filing states an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that disaggregated certain subsidiaries' holdings from The Vanguard Group, Inc. The Schedule lists the filing address as 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
The filing declares no sole or shared voting or dispositive power over any Revolution Medicines shares and confirms ownership of 5% or less of the class.
Revolution Medicines, Inc. officer Anthony Mancini exercised options and sold shares of common stock. He exercised options for 37,450 shares of common stock at an exercise price of $33.6200 per share and received 37,450 shares.
On the same date, he sold a total of 37,450 shares in multiple open-market transactions at prices ranging from $93.2230 to $97.2071, pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025. After these transactions, he directly holds 54,800 shares of common stock, which the footnotes state includes 54,400 restricted stock units.
Revolution Medicines, Inc. officer Anthony Mancini exercised options and sold shares of common stock. He exercised options for 37,450 shares of common stock at an exercise price of $33.6200 per share and received 37,450 shares.
On the same date, he sold a total of 37,450 shares in multiple open-market transactions at prices ranging from $93.2230 to $97.2071, pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025. After these transactions, he directly holds 54,800 shares of common stock, which the footnotes state includes 54,400 restricted stock units.
Revolution Medicines, Inc. officer Anthony Mancini filed an initial statement of beneficial ownership, detailing his existing equity position rather than reporting new trades. He directly holds 54,400 shares of Common Stock as Restricted Stock Units.
He also holds stock options over 149,800 shares of Common Stock at an exercise price of $33.62 per share, expiring on March 31, 2035. Twenty-five percent of these option shares vest on the first anniversary of the April 1, 2025 vesting commencement date, with the remainder vesting monthly over four years.
A separate stock option covers 26,200 shares of Common Stock at an exercise price of $102.02 per share, expiring on February 28, 2036. One forty-eighth of these shares vests on each monthly anniversary of the March 1, 2026 vesting commencement date, so they become fully vested after four years of continued service.
Revolution Medicines, Inc. officer Anthony Mancini filed an initial statement of beneficial ownership, detailing his existing equity position rather than reporting new trades. He directly holds 54,400 shares of Common Stock as Restricted Stock Units.
He also holds stock options over 149,800 shares of Common Stock at an exercise price of $33.62 per share, expiring on March 31, 2035. Twenty-five percent of these option shares vest on the first anniversary of the April 1, 2025 vesting commencement date, with the remainder vesting monthly over four years.
A separate stock option covers 26,200 shares of Common Stock at an exercise price of $102.02 per share, expiring on February 28, 2036. One forty-eighth of these shares vests on each monthly anniversary of the March 1, 2026 vesting commencement date, so they become fully vested after four years of continued service.
Revolution Medicines, Inc. Chief Medical Officer Wei Lin reported an open-market sale of 2,073 shares of common stock on March 17, 2026 at an average price of $99.4804 per share. The transaction was made under a pre-arranged Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy tax withholding obligations upon the vesting of restricted stock units after March 15, 2025. Following this sale, Lin holds 101,366 shares directly, which the disclosure states includes 62,050 restricted stock units.
Revolution Medicines, Inc. Chief Medical Officer Wei Lin reported an open-market sale of 2,073 shares of common stock on March 17, 2026 at an average price of $99.4804 per share. The transaction was made under a pre-arranged Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy tax withholding obligations upon the vesting of restricted stock units after March 15, 2025. Following this sale, Lin holds 101,366 shares directly, which the disclosure states includes 62,050 restricted stock units.
Revolution Medicines, Inc. officer Stephen Michael Kelsey reported an open-market sale of 4,302 shares of Common Stock at 99.4804 per share. The transaction was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations upon vesting of restricted stock units. After this sale, he directly owns 295,398 shares, which includes 84,250 restricted stock units.
Revolution Medicines, Inc. officer Stephen Michael Kelsey reported an open-market sale of 4,302 shares of Common Stock at 99.4804 per share. The transaction was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations upon vesting of restricted stock units. After this sale, he directly owns 295,398 shares, which includes 84,250 restricted stock units.
Revolution Medicines director Mark A. Goldsmith sold 12,871 shares of common stock in an open-market transaction at an average price of $99.4804 per share on March 17, 2026. The sale was made under a Rule 10b5-1 instruction letter to satisfy tax withholding obligations from vesting restricted stock units.
After the sale, he holds 276,698 shares directly, including 201,150 RSUs. He also has indirect holdings through trusts, with reported positions of 594,060, 64,424, and 64,424 shares of common stock held in separate revocable trusts.
Revolution Medicines director Mark A. Goldsmith sold 12,871 shares of common stock in an open-market transaction at an average price of $99.4804 per share on March 17, 2026. The sale was made under a Rule 10b5-1 instruction letter to satisfy tax withholding obligations from vesting restricted stock units.
After the sale, he holds 276,698 shares directly, including 201,150 RSUs. He also has indirect holdings through trusts, with reported positions of 594,060, 64,424, and 64,424 shares of common stock held in separate revocable trusts.